Vanguard reports 5.05% stake in Ionis Pharmaceuticals
Vanguard Capital Management reported beneficial ownership of 8,344,732 shares of Ionis Pharmaceuticals common stock, representing 5.05% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vanguard Capital Management reported beneficial ownership of 8,344,732 shares of Ionis Pharmaceuticals common stock, representing 5.05% of the class. The filing lists sole voting power over 1,226,402 shares and sole dispositive power over 8,344,732 shares. The Schedule 13G is signed by Vanguard's Head of Global Fund Administration.
Insights
Vanguard holds a passive, disclosed >5% stake in Ionis (5.05%).
Vanguard Capital Management reports 8,344,732 shares beneficially owned with sole dispositive power, indicating control over disposition decisions for these shares. The record shows limited sole voting power (1,226,402 shares), consistent with fund structures.
Because this is a Schedule 13G disclosure, the position is presented as passive under the applicable reporting standard; subsequent filings could show changes if Vanguard moves to active status.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficial ownership financial
Sole dispositive power regulatory
Sole voting power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Vanguard hold in Ionis Pharmaceuticals (IONS)?
Who signed the 13G filing for Vanguard on Ionis (IONS)?
How much voting power does Vanguard have in Ionis as reported?
AI-generated analysis. How Rhea-AI works. Not financial advice.